Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 12/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825830 | 0.85 | GPR119 (0.54) | LNPEPGPR119 | |
| SCHEMBL29826207 | 0.84 | EPHX2 (0.42) | GPR119 | |
| SCHEMBL30745372 | 0.84 | LNPEP (0.39) | LNPEPGPR119 | |
| SCHEMBL26669357 | 0.84 | GPR119 (0.44) | GPR119 | |
| SCHEMBL26669366 | 0.84 | GPR119 (0.44) | GPR119 | |
| SCHEMBL24791730 | 0.83 | PIK3CD (0.48) | LNPEPGPR119 | |
| SCHEMBL30111143 | 0.83 | PIK3CD (0.48) | LNPEPGPR119 | |
| SCHEMBL29157077 | 0.83 | PIK3CD (0.48) | LNPEPGPR119 | |
| SCHEMBL27477980 | 0.83 | USP30 (0.38) | LNPEPGPR119 | |
| SCHEMBL29826353 | 0.81 | GPR119 (0.40) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | LNPEP 1845/4885GPR119 4/4885 |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | LNPEP 1845/4885GPR119 4/4885 |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | LNPEP 1845/4885GPR119 4/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | LNPEP 1845/4885GPR119 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.